Otsuka Pharmaceutical and H. Lundbeck have announced marketing authorization approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of ...
Germany-based Bayer HealthCare and US-based Onyx Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Nexavar (sorafenib), an oral multi-kinase inhibitor, for the treatment of patients with ...
Johnson & Johnson (JNJ) subsidiary Janssen Biotech and Pharmacyclics (PCYC) have won approval from the US Food and Drug Administration (FDA) for their breakthrough therapy Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma ...
Tags: Johnson&Johnson, MCL Patients
Switzerland-based Helsinn group has granted Chugai Pharma Marketing, a wholly-owned subsidiary of Chugai Pharmaceutical, exclusive commercialization rights to their ghrelin receptor agonist, anamorelin, for the three major European pharma ...
Tags: Helsinn group, Pharma Marketing
Discovery Laboratories, a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, has announced that the US Food and Drug Administration (FDA) has cleared the company's investigational new drug ...
Tags: Discovery Labs, Medicine
The Brain & Behavior Research Foundation (BBRF) (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of president and CEO Dr Jeffrey Borenstein, has announced the latest ...
Tags: Narsad, BBRF, investigator, award
Pulmatrix has released positive results from initial stage of Phase IB clinical trial of a bronchodilator therapy PUR0200 for patients with chronic obstructive pulmonary disease (COPD). The company said PUR0200 is the first small molecule ...
Senesco Technologies reported the treatment of the first patient at the Company’s newly opened clinical-trial site at Seattle Cancer Care Alliance (SCCA). This patient is part of Senesco’s Phase 1b/2a clinical study of its ...
Tags: Senesco, Clinical Trial
Ranbaxy Laboratories has secured approval from India's Central Drugs Standard Control Organisation (CDSCO) to manufacture and sell 'Synriam' to treat uncomplicated malaria caused by Plasmodium vivax parasite in adult patients. Phase III ...
Tags: Ranbaxy Laboratories, Drug Synriam
US-based clinical development firm AltheRx Pharmaceuticals has received a notice of allowance for its patent application from the US Patent and Trademark Office (USPTO) for the use of solabegron in combination with antimuscarinics at both ...
The US Food and Drug Administration (FDA) has approved Antares Pharma's (Antares) OTREXUP, a single-dose, disposable auto-injector for the subcutaneous (SC) once-weekly administration of methotrexate (MTX). OTREXUP is reportedly the first ...
Cornerstone Pharmaceuticals has received the US Food and Drug Administration (FDA) orphan drug designation for its altered energy metabolism directed (AEMD) drug candidate 'CPI-613' for treatment of myelodysplastic syndrome (MDS). MDS is ...
Biopharmaceutical company Trigemina will deliver clinical data on its drug candidate TI-001 for the treatment of chronic migraine at the ongoing 7th Annual Pain Therapeutics Summit East in Boston, Massachusetts. The presentation will ...
Tags: Migraine Drug, Medicine
NovaDigm Therapeutics has started a Phase Ib/IIa clinical trial of its NDV-3 vaccine, which is being developed to prevent episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). Under the trial, which is a ...
Tags: NDV-3 Vaccine, NovaDigm
Galectin Therapeutics has reported a net loss of $2.54m, or $0.72 per share, for the second quarter ended on 30 June 2013 compared to a net loss of $2.66m, or $0.19 per share, in 2012. Total operating loss for the second quarter ended 30 ...